Cargando…
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
Phenylketonuria (PKU), a deficiency in the activity of the enzyme phenylalanine hydroxylase, leads to toxic levels of phenylalanine (Phe) in the blood and brain. Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with polyethylene glycol) is approved to manage PKU in...
Autores principales: | Qi, Yulan, Patel, Gina, Henshaw, Joshua, Gupta, Soumi, Olbertz, Joy, Larimore, Kevin, Harding, Cary O., Merilainen, Markus, Zori, Roberto, Longo, Nicola, Burton, Barbara K., Li, Mingjin, Gu, Zhonghua, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504851/ https://www.ncbi.nlm.nih.gov/pubmed/34057292 http://dx.doi.org/10.1111/cts.13043 |
Ejemplares similares
-
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
por: Gupta, Soumi, et al.
Publicado: (2018) -
A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences
por: Sri Bhashyam, Sumitra, et al.
Publicado: (2019) -
Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria
por: Zori, Roberto, et al.
Publicado: (2019) -
Evidence- and consensus-based recommendations for the use of
pegvaliase in adults with phenylketonuria
por: Longo, Nicola, et al.
Publicado: (2018) -
Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
por: Longo, Nicola, et al.
Publicado: (2018)